Alendronate treatment for osteoporosis: a review of the clinical evidence.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 9116385.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Bisphosphonates have recently gained an increasing role in the management of osteoporosis. The aminobisphosphonate, alendronate has recently been introduced as a new agent for the treatment of postmenopausal osteoporosis. This paper reviews the clinical evidence for the use of this agent and seeks to assess its place in osteoporosis management.
Medical subject headings
- Alendronate
- Osteoporosis